Location of Repository

Nociceptin/orphanin FQ receptor ligands: pharmacological studies

By Carmela Fischetti

Abstract

The neuropeptide nociceptin/orphanin FQ (N/OFQ) selectively binds and activates the N/OFQ peptide (NOP) receptor. At the cellular level N/OFQ inhibits cAMP accumulation and Caˆ{2,+} conductance and stimulates K ˆ+ currents. N/OFQ regulates several biological functions both at central (pain, locomotion, memory, emotional responses, food intake) and peripheral (airways, cardiovascular, genitourinary and gastrointestinal systems) sites. Potent and selective NOP ligands are now required for investigating the roles played by NOP receptors in pathophysiological studies and for firmly defining the therapeutic indications of NOP receptor ligands.\ud \ud A novel assay to screen NOP receptor ligands has been validated with a large panel of ligands: the G\alpha_{q,I,5} chimeric protein has been used to force the NOP receptor to signal through the Ca ˆ{2,+} pathway in CHO cells. [Ca ˆ{2,+}]_i levels were monitored using the\ud fluorometer FlexStation II. Data are in general agreement with classical Gi driven assay systems.\ud \ud The NOP peptide partial agonist, ZP120 was extensively characterized in vitro using electrically stimulated isolated tissues (mouse and rat vas deferens) and in vivo with the tail withdrawal assay. The selective involvement of the NOP receptor in the actions of ZP120 has been demonstrated in NOP(-/-) mice studies.\ud \ud A detailed pharmacological characterization of the recently identified non-peptide antagonist Compound 24 has been performed. Moreover in the context of a SAR study on\ud Compound 24, a novel NOP ligand named Compound 35 was identified. Compound 24 and Compound 35 bound the human recombinant NOP receptor expressed in CHO_{h,N,O,P} cell membranes with high affinity (pK_i values 9.62 and 9.14, respectively). Our findings derived from functional studies on CHO_{h,N,O,P} and bioassay studies on native receptors demonstrated that Compound 24 and Compound 35 behave as potent, competitive and selective non-peptide NOP antagonists. Finally, the NOP antagonist properties of Compound 24 have been confirmed in vivo in the mouse tail withdrawal assay

Publisher: University of Leicester
Year: 2009
OAI identifier: oai:lra.le.ac.uk:2381/7446

Suggested articles

Preview

Citations

  1. (2000). [3H]ac-RYYRWK-NH2, a novel specific radioligand for the nociceptin/orphanin FQ receptor.
  2. (2002). [Nphe1,Arg14,Lys15]nociceptin-NH2, a novel potent and selective antagonist of the nociceptin/orphanin FQ receptor.
  3. (2000). 4-Aminoquinolines: novel nociceptin antagonists with analgesic activity.
  4. (1999). 8-acenaphthen-1-yl-1-phenyl-1,3,8-triaza-spiro[4.5]decan-4-one derivatives as orphanin FQ receptor agonists.
  5. (2000). 8-Naphthalen-1-ylmethyl-4-oxo-1-phenyl-1,3,8-triazaspiro[4. 5]dec-3-yl)-acetic acid methyl ester (NNC 63-0532) is a novel potent nociceptin receptor agonist.
  6. (1998). A new selective antagonist of the nociceptin receptor.
  7. (2004). A Pharmacology Primer.
  8. (2000). A synthetic agonist at the orphanin FQ/nociceptin receptor ORL1: anxiolytic profile in the rat.
  9. (2003). Acquisition, expression, and reinstatement of ethanol-induced conditioned place preference in mice: effects of opioid receptor-like 1 receptor agonists and naloxone.
  10. (1997). Actions of the ORL1 receptor ligand nociceptin on membrane properties of rat periaqueductal gray neurons in vitro.
  11. (1997). Address and message sequences for the nociceptin receptor: a structure-activity study of nociceptin-(1-13)-peptide amide.
  12. (2006). Agonist-regulated endocytosis and desensitization of the human nociceptin receptor.
  13. (1999). Agonistic effect of buprenorphine in a nociceptin/OFQ receptor-triggered reporter gene assay.
  14. (1998). Analgesic activity of orphanin FQ2, murine prepro-orphanin FQ141-157 in mice.
  15. (1997). Anatomical distribution of mu, delta, and kappa opioid- and nociceptin/orphanin FQ-stimulated [35S]guanylyl-5'-O-(gamma-thio)-triphosphate binding in guinea pig brain.
  16. (2001). Antagonism of ORLI receptor produces an algesic effect in the rat formalin test.
  17. (2000). Antagonistic effects of [Nphe1]nociceptin(1-13)NH2 on nociceptin receptor mediated inhibition of cAMP formation in Chinese hamster ovary cells stably expressing the recombinant human nociceptin receptor.
  18. (2002). Antagonistic effects of CompB on orphanin FQ-induced colonic contractions in rats.
  19. (1998). Anti-nociceptive responses produced by human putative counterpart of nocistatin.
  20. (2008). Antinociceptive effects of nociceptin/orphanin FQ receptor agonists in the mouse writhing test
  21. (1999). Antinociceptive effects of the ORL1 receptor agonist nociceptin/orphanin FQ in diabetic mice.
  22. (2002). Antitussive effect of nociceptin/orphanin FQ in experimental cough models.
  23. (2004). Antitussive profile of the NOP agonist Ro-64-6198 in the guinea pig.
  24. (2008). Anxiolytic- and antidepressant-like activities of UFP-512, a novel selective delta opioid receptor agonist.
  25. (2006). Anxiolytic-like effects of nociceptin/orphanin FQ in the elevated plus maze and in the conditioned defensive burying test in rats.
  26. (2002). Arg(14),Lys(15)]nociceptin, a highly potent agonist of the nociceptin/orphanin FQ receptor: in vitro and in vivo studies.
  27. (1997). Association of aminopeptidase N and endopeptidase 24.15 inhibitors potentiate behavioral effects mediated by nociceptin/orphanin FQ in mice.
  28. (2000). Autoradiographic localization of (125)I[Tyr(14)]orphanin FQ/nociceptin and (125)I[Tyr(10)]orphanin FQ/nociceptin(1-11) binding sites in rat brain.
  29. (2004). Behavioral and endocrine
  30. (1997). Bidirectional modulatory effect of orphanin FQ on morphine-induced analgesia: antagonism in brain and potentiation in spinal cord of the rat.
  31. (1997). Binding and in vitro activities of peptides with high affinity for the nociceptin/orphanin FQ receptor, ORL1.
  32. (2004). Blockade of nociceptin/orphanin FQ receptor signaling in rat substantia nigra pars reticulata stimulates nigrostriatal dopaminergic transmission and motor behavior.
  33. (2005). Blockade of nociceptin/orphanin FQ transmission attenuates symptoms and neurodegeneration associated with Parkinson's disease.
  34. (2004). Blockade of nociceptin/orphanin FQ transmission in rat substantia nigra reverses haloperidol-induced akinesia and normalizes nigral glutamate release.
  35. (2007). Buprenorphine reduces alcohol drinking through activation of the nociceptin/orphanin FQ-NOP receptor system.
  36. (2003). Buprenorphine-induced antinociception is mediated by mu-opioid receptors and compromised by concomitant activation of opioid receptor-like receptors.
  37. (1999). Cardiovascular and renal responses produced by central orphanin FQ/nociceptin occur independent of renal nerves.
  38. (1999). Cardiovascular effects of nociceptin in unanesthetized mice.
  39. (1994). cDNA cloning of an orphan opiate receptor gene family member and its splice variant.
  40. (2000). Cellular actions of nociceptin: transduction mechanisms.
  41. (1999). Central administration of [Phe1psi(CH2-NH)Gly2]nociceptin(1-13)-NH2 and orphanin FQ/nociceptin (OFQ/N) produce similar cardiovascular and renal responses in conscious rats.
  42. (2004). Central administration of nociceptin/orphanin FQ blocks the acquisition of conditioned place preference to morphine and cocaine, but not conditioned place aversion to naloxone in mice.
  43. (2000). Characterization of [Nphe(1)]nociceptin(1-13)NH(2), a new selective nociceptin receptor antagonist.
  44. (1999). Characterization of nociceptin receptors in the periphery: in vitro and in vivo studies.
  45. (2001). Characterization of opiates, neuroleptics, and synthetic analogs at ORL1 and opioid receptors.
  46. (2001). Characterization of the locomotor activity-inhibiting effect of nociceptin/orphanin FQ in mice.
  47. (2005). Characterization of the nociceptin receptor (ORL-1) agonist, Ro64-6198, in tests of anxiety across multiple species. Psychopharmacology (Berl).
  48. (1999). Chimeric G proteins allow a high-throughput signaling assay of Gi-coupled receptors.
  49. (2008). Chronic treatment with [Nphe1, Arg14, Lys15] N/OFQ-NH2 (UFP101), a potent NOP receptor antagonist, reverses behavioral and biochemical effects in the rat chronic mild stress.In EOC-ENC.
  50. (2004). Circulating nociceptin levels during the cluster headache period.
  51. (1993). Cloning and functional comparison of kappa and delta opioid receptors from mouse brain.
  52. (1992). Cloning of a delta opioid receptor by functional expression.
  53. (1999). Cloning, expression and functional role of a nociceptin/orphanin FQ receptor in the porcine gastrointestinal tract.
  54. (2002). Comparison of the ORL1 receptor-mediated inhibition of noradrenaline release in human and rat neocortical slices.
  55. (2006). Coupling of ORL1 (NOP) receptor to G proteins is decreased in the nucleus accumbens of anxious relative to non-anxious mice.
  56. (2006). Daily intravesical instillation of 1 mg
  57. (2002). Degradation of nociceptin (orphanin FQ) by mouse spinal cord synaptic membranes is triggered by endopeptidase-24.11: an in vitro and in vivo study.
  58. (2008). Designed modification of partial agonist of ORL1 nociceptin receptor for conversion into highly potent antagonist.
  59. (2000). Direct identification of a peptide binding region in the opioid receptor-like 1 receptor by photoaffinity labeling with [Bpa(10),Tyr(14)]nociceptin.
  60. (1999). Discovery of the first potent and selective small molecule opioid receptor-like (ORL1) antagonist: 1-[(3R,4R)-1-cyclooctylmethyl-3- hydroxymethyl-4-piperidyl]-3-ethyl-1, 3-dihydro-2H-benzimidazol-2-one (J-113397).
  61. (1999). Distinct effect of intracerebroventricular and intrathecal injections of nociceptin/orphanin FQ in the rat formalin test.
  62. (2001). Distribution and chemical coding of orphanin FQ/nociceptin-immunoreactive neurons in the myenteric plexus of guinea pig intestines and sphincter of Oddi.
  63. (2004). Distribution of nociceptin/orphanin FQ in adult human brain.
  64. (1998). Distribution of nociceptin/orphanin FQ receptor transcript in human central nervous system and immune cells.
  65. (1997). Diuretic and antinatriuretic responses produced by the endogenous opioid-like peptide, nociceptin (orphanin FQ).
  66. (2000). Drug discovery: a historical perspective.
  67. (2008). Effect of compound 24, a novel nociceptin/orphanin FQ (NOP) receptor antagonist, on NOP receptor-mediated k+ channel activation in rat periaqueductal gray slices.
  68. (2003). Effect of JTC-801 (nociceptin antagonist) on neuropathic pain in a rat model.
  69. (1999). Effect of nociceptin on alcohol intake in alcohol-preferring rats.
  70. (1997). Effect of nociceptin on heart rate and blood pressure in anaesthetized rats.
  71. (2006). Effect of novel nociceptin/orphanin FQ-NOP receptor ligands on ethanol drinking in alcohol-preferring msP rats.
  72. (2006). Effect of novel NOP receptor ligands on food intake in rats.
  73. (2006). Effect of the Nociceptin / Orphanin FQ receptor ligand Ac-Cit-D-Cha-Qaa-DArg-D-p-Clphe-NH2 in electrically stimulated isolated tissues.
  74. (2002). Effects of [(pF)Phe(4)]nociceptin/orphanin FQ-(1-13)NH(2) on GTPgamma(35)S binding and cAMP formation in Chinese hamster ovary cells expressing the human nociceptin/orphanin FQ receptor.
  75. (2000). Effects of an antisense oligonucleotide to pronociceptin and long-term prevention of morphine actions by nociceptin.
  76. (2006). Effects of Intrathecally Administered Nociceptin/Orphanin FQ in Monkeys: Behavioral and Mass Spectrometric Studies.
  77. (2004). Effects of nociceptin on the exploratory behavior of mice in the hole-board test.
  78. (1999). Effects of nocistatin on nociceptin-induced impairment of learning and memory in mice.
  79. (2001). Effects of Ro 64-6198 in nociceptin/orphanin FQ-sensitive isolated tissues.
  80. (1997). Effects of sigma ligands on the nociceptin/orphanin FQ receptor co-expressed with the G-protein-activated K+ channel in Xenopus oocytes.
  81. (2001). Endogenous nociceptin signaling and stress-induced analgesia.
  82. (2006). Endogenous nociceptin/orphanin FQ signalling produces opposite spinal antinociceptive and supraspinal pronociceptive effects in the mouse formalin test: pharmacological and genetic evidences.
  83. (2000). Enhanced spinal nociceptin receptor expression develops morphine tolerance and dependence.
  84. (1998). Enhancement of spatial attention in nociceptin/orphanin FQ receptor-knockout mice.
  85. (1998). Evidence that [Phe1 psi(CH2-NH)Gly2]nociceptin(1-13)-NH2, a peripheral ORL-1 receptor antagonist, acts as an agonist in the rat spinal cord.
  86. (1995). Expression of alternate forms of brain opioid 'orphan' receptor mRNA in activated human peripheral blood lymphocytes and lymphocytic cell lines.
  87. (1998). Facilitation of long-term potentiation and memory in mice lacking nociceptin receptors.
  88. (1998). Functional blockade of opioid analgesia by orphanin FQ/nociceptin.
  89. (2005). Functional Selectivity of Nociceptin/Orphanin FQ Peptide Receptor Partial Agonists on Cardiovascular and Renal Function.
  90. (1999). Functional significance of a newly discovered neuropeptide, orphanin FQ, in rat gastrointestinal motility.
  91. (2000). Further studies on nociceptin-related peptides: discovery of a new chemical template with antagonist activity on the nociceptin receptor.
  92. (2009). Further studies on the pharmacological features of the nociceptin/orphanin FQ receptor ligand ZP120. Peptides.
  93. (2002). Gastric acid secretion stimulated by centrally injected nociceptin in urethane-anesthetized rats.
  94. (2005). GPCR deorphanizations: the novel, the known and the unexpected transmitters.
  95. (2000). Highly potent nociceptin analog containing the Arg-Lys triple repeat.
  96. (1998). Identification and differential regional expression of KOR-3/ORL-1 gene splice variants in mouse brain.
  97. (2003). Identification of a hexapeptide binding region in the nociceptin (ORL1) receptor by photo-affinity labelling with Ac-Arg-Bpa-Tyr-Arg-Trp-Arg-NH2.
  98. (2006). Identification of an achiral analogue of J-113397 as potent nociceptin/orphanin FQ receptor antagonist.
  99. (1996). Immunohistochemical localization of ORL-1 in the central nervous system of the rat.
  100. (2006). Immunolocalization of orphanin FQ in rat cochlea.
  101. (2003). Impact of environmental housing conditions on the emotional responses of mice deficient for nociceptin/orphanin FQ peptide precursor gene.
  102. (1993). In situ hybridization study of kappa-opioid receptor mRNA in the rat brain.
  103. (1999). In vitro agonist effects of nociceptin and [Phe(1)psi(CH(2)-NH)Gly(2)]nociceptin(1-13)NH(2) in the mouse and rat colon and the mouse vas deferens.
  104. (2008). In vitro and in vivo characterization of the NOP receptor non peptide antagonist Compound 24. Society for Neuroscience,
  105. (2000). In vitro and in vivo pharmacological characterization of J-113397, a potent and selective non-peptidyl ORL1 receptor antagonist.
  106. (2006). In vitro and in vivo pharmacological characterization of the nociceptin/orphanin FQ receptor ligand AcRYYRIK-ol.
  107. (2006). In vitro and in vivo pharmacological characterization of the novel UT receptor ligand [Pen(5),DTrp(7),Dab(8)]urotensin II(4-11) (UFP-803).
  108. (2007). In vitro and in vivo studies on UFP-112, a novel potent and long lasting agonist selective for the nociceptin/orphanin FQ receptor.
  109. In vitro and in vivo studies on UFP112, a novel potent and long lasting agonist selective for the nociceptin/orphanin FQ receptor.
  110. (2001). In vitro characterization of AcRYYRWK-NH(2), Ac-RYYRIK-NH(2) and [Phe1Psi(CH(2)-NH)Gly2] nociceptin(1-13)NH(2) at rat native and recombinant ORL(1) receptors.
  111. (2000). In vitro characterization of J-113397, a nonpeptide nociceptin/orphanin FQ receptor antagonist.
  112. (2000). In vitro pharmacological profile of peptide III-BTD: a novel ligand for nociceptin/orphanin FQ and opioid receptors.
  113. (1996). Increase by the ORL1 receptor (opioid receptor-like1) ligand, nociceptin, of inwardly rectifying K conductance in dorsal raphe nucleus neurones.
  114. (1996). Inhibition of tachykinin release from peripheral endings of sensory nerves by nociceptin, a novel opioid peptide.
  115. (2001). Inhibitory activity of nociceptin/orphanin FQ on capsaicin-induced bronchoconstriction in the guinea-pig.
  116. (2003). International Union of Pharmacology Committee on Receptor Nomenclature and Drug Classification. XXXVIII. Update on terms and symbols in quantitative pharmacology.
  117. (1996). International Union of Pharmacology. XII. Classification of opioid receptors.
  118. (1999). Intracerebroventricular administration of nocistatin reduces inflammatory hyperalgesia in rats.
  119. (1986). Intracerebroventricular injections in mice. Some methodological refinements.
  120. Intrathecal [Nphe1]nociceptin( 1-13)NH2 selectively reduces the spinal inhibitory effect of nociceptin.
  121. (1997). Involvement of endogenous orphanin FQ in electroacupuncture-induced analgesia.
  122. (2008). Involvement of the GABA/benzodiazepine receptor in the axiolytic-like effect of nociceptin/orphanin FQ.
  123. (1995). Isolation and structure of the endogenous agonist of opioid receptor-like ORL1 receptor.
  124. (1994). Isolation of a novel cDNA encoding a putative membrane receptor with high homology to the cloned mu, delta, and kappa opioid receptors.
  125. (1980). Isolation of two novel candidate hormones using a chemical method for finding naturally occurring polypeptides.
  126. (1999). Localization of orphanin FQ (nociceptin) peptide and messenger RNA in the central nervous system of the rat.
  127. (1998). Loss of antinociception induced by naloxone benzoylhydrazone in nociceptin receptorknockout mice.
  128. (2004). Minireview: Characterization of influence of central nociceptin/orphanin FQ on consummatory behavior.
  129. (2004). Modification of nociception and morphine tolerance by the selective opiate receptor-like orphan receptor antagonist (-)-cis-1-methyl7-[[4-(2,6-dichlorophenyl)piperidin-1-yl]methyl]-6,7,8,9- tetrahydro-5Hbenzocyclohepten-5-ol (SB-612111).
  130. (1996). Modulation of voltage-gated calcium channels by orphanin FQ in freshly dissociated hippocampal neurons.
  131. (1995). Molecular cloning of a novel G protein-coupled receptor related to the opiate receptor family.
  132. (2001). Molecular cloning of the orphanin FQ receptor gene and differential tissue expression of splice variants in rat.
  133. (1998). Molecular modelling of the ORL1 receptor and its complex with nociceptin.
  134. (2001). Morphine tolerance and dependence in nociceptin/orphanin FQ transgenic knock-out mice.
  135. (1996). Multiple opioid receptor-like genes are identified in diverse vertebrate phyla.
  136. (2005). N- and C-terminal modifications of nociceptin/orphanin FQ generate highly potent NOP receptor ligands.
  137. (2003). N-terminal modifications leading to peptide ORL1 partial agonists and antagonists.
  138. (2000). Neurohumoral effects of orphanin FQ/nociceptin: relevance to cardiovascular and renal function.
  139. (1998). New 2-oxoimidazole derivatives - are nociceptin receptor binding inhibitors useful e.g. as analgesics and for amelioreting brain function.
  140. (2005). Nociceptin / Orphanin FQ receptor antagonists as a novel therapeutic approach to Parkinson’s disease.
  141. (2000). Nociceptin and the micturition reflex.
  142. (2008). Nociceptin and urotensin-II concentrations in critically ill patients with sepsis.
  143. (2004). Nociceptin antagonism: probing the receptor by N-acetyl oligopeptides.
  144. (1999). Nociceptin augments K(+) currents in hippocampal CA1 neurons by both ORL-1 and opiate receptor mechanisms.
  145. (1998). Nociceptin fails to affect heroin self-administration in the rat.
  146. (1997). Nociceptin hyperpolarises neurones in the rat ventromedial hypothalamus.
  147. Nociceptin inhibits cough in the guinea-pig by activation of ORL(1) receptors.
  148. (2000). Nociceptin inhibits electric field stimulation-induced cholinergic constrictions in rat airways.
  149. (2002). Nociceptin inhibits excitatory but not inhibitory transmission to substantia gelatinosa neurones of adult rat spinal cord.
  150. (2000). Nociceptin inhibits rat sympathetic preganglionic neurons in situ and in vitro.
  151. (1999). Nociceptin modulates renal sympathetic nerve activity through a central action in conscious rats.
  152. (1996). Nociceptin or antinociceptin: potent spinal antinociceptive effect of orphanin FQ/nociceptin in the rat.
  153. (2000). Nociceptin prevents stress-induced ethanol- but not cocaine-seeking behavior in rats.
  154. (1999). Nociceptin receptor activation inhibits tachykinergic non adrenergic non cholinergic contraction of guinea pig isolated bronchus.
  155. (2002). Nociceptin receptor antagonists display antidepressant-like properties in the mouse forced swimming test.
  156. (1996). Nociceptin receptor coupling to a potassium conductance in rat locus coeruleus neurones in vitro.
  157. (1999). Nociceptin system plays a role in the memory retention: involvement of naloxone benzoylhydrazone binding sites.
  158. (1998). Nociceptin-induced inhibition of tachykinergic neurotransmission in guinea pig bronchus.
  159. (1997). Nociceptin: an endogenous agonist for central opioid like1 (ORL1) receptors possesses systemic vasorelaxant properties.
  160. (2003). Nociceptin/orphanin FQ and its receptor--potential targets for pain therapy?
  161. (2000). Nociceptin/orphanin FQ and neurotransmitter release in the central nervous system.
  162. (1999). Nociceptin/orphanin FQ and nocistatin on learning and memory impairment induced by scopolamine in mice.
  163. (1996). Nociceptin/orphanin FQ and opioid peptides show overlapping distribution but not co-localization in painmodulatory brain regions.
  164. (1997). Nociceptin/orphanin FQ and the opioid receptor-like ORL1 receptor.
  165. (2001). Nociceptin/orphanin FQ exacerbates excitotoxic white-matter lesions in the murine neonatal brain.
  166. (2004). Nociceptin/orphanin FQ increases anxiety-related behavior and circulating levels of corticosterone during neophobic tests of anxiety.
  167. (2002). Nociceptin/orphanin FQ inhibits capsaicin-induced guinea-pig airway contraction through an inward-rectifier potassium channel.
  168. (2001). Nociceptin/orphanin FQ inhibits stress- and CRF-induced anorexia in rats.
  169. (2000). Nociceptin/orphanin FQ metabolism and bioactive metabolites.
  170. (1997). Nociceptin/orphanin FQ metabolism: role of aminopeptidase and endopeptidase 24.15.
  171. (1997). Nociceptin/orphanin FQ microinjected into hippocampus impairs spatial learning in rats.
  172. (2002). Nociceptin/orphanin FQ modulates the cardiovascular, but not renal, responses to stress in spontaneously hypertensive rats.
  173. (2008). Nociceptin/orphanin FQ peptide receptor as a therapeutic target for obesity.
  174. (2006). Nociceptin/orphanin FQ presynaptically decreases GABAergic transmission and blocks the ethanol-induced increase of GABA release in central amygdala.
  175. (2005). Nociceptin/orphanin FQ prevents ethanol-induced gastric lesions in the rat.
  176. (2008). Nociceptin/orphanin FQ receptor blockade attenuates MPTP-induced parkinsonism.
  177. (2005). Nocistatin inhibits 5-hydroxytryptamine release in the mouse neocortex via G protein coupled presynaptic receptors.
  178. Nocistatin inhibits 5-hydroxytryptamine release in the mouse neocortex via presynaptic Gi/o protein linked pathways.
  179. (2000). Nocistatin inhibits food intake in rats.
  180. (1998). Nocistatin reverses nociceptin inhibition of glutamate release from rat brain slices.
  181. (1998). Nocistatin, a peptide that blocks nociceptin action in pain transmission.
  182. (2003). Non-peptidergic OP4 receptor agonist inhibits morphine antinociception but does not influence morphine dependence.
  183. (2004). Nonpeptide/peptide chimeric ligands for the nociceptin/orphanin FQ receptor: design, synthesis and in vitro pharmacological activity.
  184. (1999). Novel 1,3,8-triazaspiro[4,5]deconones with affinity for opiod receptor subtypes.
  185. (2002). Novel, potent ORL-1 receptor agonist peptides containing alpha-Helix-promoting conformational constraints.
  186. (2000). Nphe(1)]-Nociceptin (1-13)-NH(2), a nociceptin receptor antagonist, reverses nociceptin-induced spatial memory impairments in the Morris water maze task in rats.
  187. (1999). Nphe(1)]nociceptin-(1-13)-NH(2) antagonizes nociceptin effects in the mouse colon.
  188. (2000). Nphe(1)]nociceptin-(1-13)NH(2) selectively antagonizes nociceptin effects in the rabbit isolated ileum.
  189. (1989). Opiate reward: sites and substrates.
  190. (2000). Opioid activity profiles indicate similarities between the nociceptin/orphanin FQ and opioid receptors.
  191. (1999). Opioid receptor-like (ORL1) receptor distribution in the rat central nervous system: comparison of ORL1 receptor mRNA expression with (125)I[(14)Tyr]-orphanin FQ binding.
  192. (1997). Opioid receptors from a lower vertebrate (Catostomus
  193. (2000). Opioid receptors.
  194. (1998). ORL-1 and mu opioid receptor antisera label different fibers in areas involved in pain processing.
  195. (1994). ORL1, a novel member of the opioid receptor family. Cloning, functional expression and localization.
  196. (1998). Orphan opioid receptor antisense probes block orphanin FQ-induced hyperphagia.
  197. (1997). Orphanin FQ acts as an anxiolytic to attenuate behavioral responses to stress.
  198. (1997). Orphanin FQ has an inhibitory effect on the guinea pig ileum and the mouse vas deferens.
  199. (2002). Orphanin FQ inhibits capsaicin-induced thermal nociception in monkeys by activation of peripheral ORL1 receptors.
  200. (1997). Orphanin FQ inhibits synaptic transmission and long-term potentiation in rat hippocampus.
  201. (1997). Orphanin FQ potentiates formalin-induced pain behavior and antagonizes morphine analgesia in rats.
  202. (1999). Orphanin FQ reduces morphine-induced dopamine release in the nucleus accumbens: a microdialysis study in rats.
  203. (1996). Orphanin FQ, agonist of orphan opioid receptor ORL1, stimulates feeding in rats.
  204. (1995). Orphanin FQ: a neuropeptide that activates an opioidlike G protein-coupled receptor.
  205. (1996). Orphanin FQ: receptor binding and analog structure activity relationships in rat brain.
  206. (2002). Orphanin FQ/nociceptin blocks cocaine-induced behavioral sensitization in rats.
  207. (2007). Orphanin FQ/nociceptin interacts with the basolateral amygdala noradrenergic system in memory consolidation.
  208. (1999). Orphanin FQ/nociceptin modulation of mesolimbic dopamine transmission determined by microdialysis.
  209. (1996). Orphanin FQ/nociceptin-immunoreactive nerve fibers parallel those containing endogenous opioids in rat spinal cord.
  210. (1997). pA, a new scale for the measurement of drug antagonism.
  211. (2003). Partial agonist behaviour depends upon the level of nociceptin/orphanin FQ receptor expression: studies using the ecdysone-inducible mammalian expression system.
  212. (2003). Peptide and nonpeptide ligands for the nociceptin/orphanin FQ receptor ORL1: research tools and potential therapeutic agents.
  213. (2001). Peptide derivatives and medicinal compositions.
  214. (1999). Peripheral and central actions of orphanin FQ (nociceptin) on murine colon.
  215. (2005). Pharmacodynamic Characterization of ZP120 (AcRYYRWKKKKKKK-NH2), a Novel, Functionally Selective Nociceptin/Orphanin FQ Peptide Receptor Partial Agonist with Sodium-Potassium-Sparing Aquaretic Activity.
  216. (2002). Pharmacological characterisation of [(pX)Phe4]nociceptin(1-13)amide analogues. 1. In vitro studies.
  217. (2002). Pharmacological characterisation of [(pX)Phe4]nociceptin(1-13)NH2 analogues. 2. In vivo studies.
  218. (1997). Pharmacological characterization of nociceptin receptor: an in vitro study.
  219. (2008). Pharmacological characterization of the newly synthesized nociceptin/orphanin FQ-receptor agonist 1-[1-(1-methylcyclooctyl)-4-piperidinyl]-2-[(3R)-3-piperidinyl]-1H-benzimidazole as an anxiolytic agent.
  220. (1998). Pharmacological characterization of the nociceptin receptor mediating hyperalgesia in the mouse tail withdrawal assay.
  221. (2000). Pharmacological characterization of the nociceptin receptor mediating hyperphagia: identification of a selective antagonist.
  222. (2007). Pharmacological Characterization of the Nociceptin/Orphanin FQ Receptor Antagonist SB-612111 [(-)-cis-1-Methyl-7-[[4-(2,6-dichlorophenyl)piperidin-1-yl]methyl]-6,7,8,9 -tetrahydro-5H-benzocyclohepten-5-ol]: In Vitro Studies.
  223. (2007). Pharmacological Characterization of the Nociceptin/Orphanin FQ Receptor Antagonist SB-612111 [(-)-cis-1-Methyl-7-[[4-(2,6-dichlorophenyl)piperidin-1-yl]methyl]-6,7,8,9 -tetrahydro-5H-benzocyclohepten-5-ol]: In Vivo Studies.
  224. Pharmacological characterization of the nociceptin/orphanin FQ receptor antagonist SB612111 [(-)-cis-1-methyl-7-[[4-(2,6-dichlorophenyl)piperidin-1-yl]methyl]-6,7,8,9-tetrahydro-5H-benzocyclohepten-5-ol]: in vitro studies.
  225. (2007). Pharmacological characterization of the nociceptin/orphanin FQ receptor antagonist SB612111: in vitro studies. Società italiana di Farmacologia,
  226. (2002). Pharmacological characterization of the novel nociceptin/orphanin FQ receptor ligand, ZP120: in vitro and in vivo studies in mice.
  227. (2002). Pharmacological profile of nociceptin/orphanin FQ receptors.
  228. (2009). Pharmacological profile of NOP receptors coupled with calcium signalling via the chimeric protein Gqi5. Naunyn-Schmiedeberg Archives of Pharmacology
  229. (2009). Pharmacological profile of NOP receptors coupled with calcium signalling via the chimeric protein Gαqi5. Naunyn Schmiedebergs Arch Pharmacol.
  230. (2002). Pharmacological profiles of a novel opioid receptor-like1 (ORL(1)) receptor antagonist, JTC-801.
  231. (2003). Pharmacological profiles of presynaptic nociceptin/orphanin FQ receptors modulating 5-hydroxytryptamine and noradrenaline release in the rat neocortex.
  232. (2008). Pharmacological properties of a novel nociceptin/orphanin FQ receptor agonist, 2-(3,5-dimethylpiperazin-1-yl)-1-[1-(1-methylcyclooctyl)piperidin-4-yl]-1H-benzim idazole, with anxiolytic potential.
  233. (2002). Pharmacological properties of nociceptin/orphanin FQinduced stimulation and inhibition of cyclic AMP formation in distinct layers of rat olfactory bulb.
  234. (1999). Pharmacological properties of TRK-820 on cloned mu-, delta- and kappaopioid receptors and nociceptin receptor.
  235. (1998). Pharmacological studies on the "orphan" opioid receptor in central and peripheral sites.
  236. (1999). Pharmacologically active peptide conjugates having reduced tendency towards enzymatic hydrolysis.
  237. (1999). Pharmacology of [Tyr1]nociceptin analogs: receptor binding and bioassay studies.
  238. (2008). Pharmacology of constitutively active NOP opioid receptors heterologously expressed in rat sympathetic neurons.
  239. (2000). Pharmacology of nociceptin and its receptor: a novel therapeutic target.
  240. (1998). Phe1psi(CH2-NH)Gly2]-nociceptin-(1-13)NH2, a proposed antagonist of the nociceptin receptor, is a potent and stable agonist in the rat spinal cord.
  241. (1998). Phe1psi(CH2-NH)Gly2]nociceptin-(1-13)-NH2 is an agonist of the nociceptin (ORL1) receptor.
  242. (2005). Plasma nociceptin levels are reduced in migraine without aura.
  243. (1978). Polypeptides of the amphibian skin active on the gut and their mammalian counterparts.
  244. (1998). Postsynaptic mechanisms underlying responsiveness of amygdaloid neurons to nociceptin/orphanin FQ.
  245. (1997). Prejunctional modulation by nociceptin of nerve-mediated inotropic responses in guinea-pig left atrium.
  246. (2003). Preparation of benzosuberonylpiperidine compounds.
  247. (1996). Primary structure and tissue distribution of the orphanin FQ precursor.
  248. (1951). Protein measurement with the Folin phenol reagent.
  249. (2002). Quantitative analysis of nociceptin in blood of patients with acute and chronic pain.
  250. (1978). Rat vas deferens: a specific bioassay for endogenous opioid peptides.
  251. (2005). Recent advances towards the discovery of ORL-1 receptor agonists and antagonists.
  252. (1997). Recognition and activation of the opioid receptor-like ORL 1 receptor by nociceptin, nociceptin analogs and opioids.
  253. (2000). Retro-nociceptin methylester, a peptide with analgesic and memory-enhancing activity.
  254. (1979). Selective receptors for beta-endorphin on the rat vas deferens.
  255. (2005). Small-molecule agonists and antagonists of the opioid receptor-like receptor (ORL1, NOP): ligand-based analysis of structural factors influencing intrinsic activity at NOP.
  256. (1997). Spinal analgesic activity of orphanin FQ/nociceptin and its fragments.
  257. (2005). Spinal and local peripheral antiallodynic activity of Ro64-6198 in neuropathic pain in the rat.
  258. Spinally delivered nociceptin/orphanin FQ reduces flinching behaviour in the rat formalin test.
  259. stimulates human monocyte chemotaxis via NOP receptor activation.
  260. (1999). Strain-dependent effects of supraspinal orphanin FQ/nociceptin on thermal nociceptive sensitivity in mice.
  261. (2005). Striatal NMDA receptors regulate the striato-pallidal pathway.
  262. (1994). Structure and chromosomal mapping of genes for the mouse kappa-opioid receptor and an opioid receptor homologue (MOR-C).
  263. (1996). Structure-activity relationship studies on the novel neuropeptide orphanin FQ.
  264. (2000). Structure-activity relationships of nociceptin and related peptides: comparison with dynorphin A.
  265. (2001). Structure-activity studies of the Phe(4) residue of nociceptin(1-13)-NH(2): identification of highly potent agonists of the nociceptin/orphanin FQ receptor.
  266. (2004). Structure-activity studies on high affinity NOP-active hexapeptides.
  267. (1998). Structure-activity study of the nociceptin(1-13)-NH2 N-terminal tetrapeptide and discovery of a nociceptin receptor antagonist.
  268. (1996). Structure, tissue distribution, and chromosomal localization of the prepronociceptin gene.
  269. Structures that delineate orphanin FQ and dynorphin A pharmacological selectivities.
  270. (2001). Studies on the antinociceptive effect of [Nphe1]nociceptin(1-13)NH2 in mice.
  271. (2001). Sturgeon orphanin, a molecular "fossil" that bridges the gap between the opioids and orphanin FQ/nociceptin.
  272. (1993). Substitution of three amino acids switches receptor specificity of Gq alpha to that of Gi alpha.
  273. (2000). Supraspinal and spinal effects of [Phe1psi(CH2-NH)Gly2]-nociceptin(1-13)-NH2 on nociception in the rat.
  274. Synthesis and biological activity of Nociceptin / Orphanin FQ analogues substituited in position 7 or 11 with Cα,α-dialkylated amino acids. Bioorg Med Chem.
  275. (1999). Targeted disruption of the orphanin FQ/nociceptin gene increases stress susceptibility and impairs stress adaptation in mice.
  276. (2005). Techniques: promiscuous Galpha proteins in basic research and drug discovery.
  277. (1957). The action of morphine and related substances on contraction and on acetylcoline output of coaxially stimulated guinea pig ileum.
  278. (2008). The anxiolytic-like effects of the novel, orally active nociceptin opioid receptor agonist 8-[bis(2-methylphenyl)methyl]-3-phenyl-8-azabicyclo[3.2.1]octan-3-ol (SCH 221510).
  279. (1992). The delta-opioid receptor: isolation of a cDNA by expression cloning and pharmacological characterization.
  280. (1996). The effect of nociceptin on
  281. (1998). The effect of nociceptin, an endogenous ligand for the ORL1 receptor, on rat colonic contraction and transit.
  282. (2000). The hyperphagic effect of nociceptin/orphanin FQ in rats.
  283. (2004). The identification of ligands at orphan G-protein coupled receptors.
  284. (1998). The inhibitory effect of nociceptin on the micturition reflex in anaesthetized rats.
  285. (2001). The molecular and behavioral pharmacology of the orphanin FQ/nociceptin peptide and receptor family.
  286. (1996). The mouse vas deferens: a pharmacological preparation sensitive to nociceptin.
  287. (2003). The neurobiology and control of anxious states.
  288. (2008). The nociceptin/orphanin FQ (NOP) receptor antagonist J-113397 enhances the effects of levodopa in the MPTP-lesioned nonhuman primate model of Parkinson's disease.
  289. (2007). The nociceptin/orphanin FQ receptor antagonist J-113397 and L-DOPA additively attenuate experimental parkinsonism through overinhibition of the nigrothalamic pathway.
  290. (2000). The nociceptin/orphanin FQ receptor antagonist, [Nphe1]NC(1-13)NH2, potentiates morphine analgesia.
  291. (2008). The nociceptin/orphanin FQ receptor: a target with broad therapeutic potential.
  292. (2004). The NOP (ORL1) receptor antagonist Compound B stimulates mesolimbic dopamine release and is rewarding in mice by a non-NOP-receptor-mediated mechanism.
  293. (2008). The novel nociceptin/orphanin FQ receptor antagonist Trap-101 alleviates experimental parkinsonism through inhibition of the nigrothalamic pathway: positive interaction with L-DOPA.
  294. (2008). The ORL-1 receptor system: are there opportunities for antagonists in pain therapy?
  295. (2008). The orphanin FQ/nociceptin (OFQ/N) system.
  296. (2002). The orphanin FQ/nociceptin knockout mouse: a behavioral model for stress responses.
  297. (2002). The orphanin receptor agonist RO 64-6198 does not induce place conditioning in rats.
  298. (2004). The pharmacology of cough.
  299. (2007). The pharmacology of Ro 64-6198, a systemically active, nonpeptide NOP receptor (opiate receptor-like 1, ORL-1) agonist with diverse preclinical therapeutic activity.
  300. (2008). The role of the opioid receptor-like (ORL1) receptor in motor stimulatory and rewarding actions of buprenorphine and morphine.
  301. (2000). Tissue distribution of the opioid receptor-like (ORL1) receptor.
  302. (1999). Tolerance develops to the inhibitory effect of orphanin FQ on morphine-induced antinociception in the rat.
  303. (2006). Tonic nociceptinergic inputs to neurons in the hypothalamic paraventricular nucleus contribute to sympathetic vasomotor tone and water and electrolyte homeostasis in conscious rats.
  304. (2000). Transcriptional regulation of the human prepronociceptin gene.
  305. (2005). Tryptophan replacement in the nociceptin/orphanin FQ receptor ligand Ac-RYYRWK-NH2.
  306. (2007). UFP-101 antagonizes the spinal antinociceptive effects of nociceptin/orphanin FQ: behavioral and electrophysiological studies in mice.
  307. (2003). UFP-101, a high affinity antagonist for the nociceptin/orphanin FQ receptor: radioligand and GTPgamma(35)S binding studies.
  308. (2005). UFP-101, a Peptide Antagonist Selective for the Nociceptin/Orphanin FQ Receptor.
  309. Unrestrained nociceptive response and disregulation of hearing ability in mice lacking the nociceptin/orphaninFQ receptor.
  310. (2003). Urodynamic effects of intravesical nociceptin/orphanin FQ in neurogenic detrusor overactivity: a randomized, placebo-controlled, double-blind study.
  311. (2008). ZP120 causes relaxation by prejunctional inhibition of noradrenergic neurotransmission in rat mesenteric resistance arteries.

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.